Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2013-04-23 Director's Dealing
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Appendix 3Y - Change in Directors Interest Notice 4 pages 676.4KB
Director's Dealing Classification · 95% confidence The document is titled 'Change in Directors Interest' and includes an Appendix 3Y Notice, which is a standard form used to report changes in directors' interests in securities. It details the securities held by Dr. Esra Ogru and associates, including shares and conditional rights, with specific dates and transaction details. The document also references the Corporations Act and ASX listing rules, indicating it is a regulatory disclosure related to insider trading or director shareholdings. There is no financial performance data, earnings information, or management discussion. The document is not an announcement of a report but a direct filing of a director's dealing in securities. Therefore, it fits the category of Director's Dealing (DIRS). The document length (8228 characters) supports it being a full notice rather than a brief announcement. Confidence is high due to the clear presence of an Appendix 3Y and detailed director interest changes.
2013-04-23 English
TPM/Diclofenac Gel - Themis in Supply Agmt with Novartis 2 pages 47.8KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phosphagenics Limited regarding a supply agreement between its partner Themis Medicare and Novartis India Limited. It is a press release-style announcement about a commercial agreement and strategic expansion of technology. There are no financial statements, regulatory certifications, voting results, or management changes. The document is relatively short (3142 characters) and does not contain detailed financial data or report content. It is an announcement of a commercial partnership and supply agreement, which fits best under the category of a general regulatory announcement or compliance document that does not fit other specific categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2013-04-14 English
POH Annual Report and AGM Documentation 131 pages 3.9MB
Regulatory Filings
2013-04-14 English
Appendix 3Y - Change of Directors Interest Notice 3 pages 439.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Change of Director’s Interest Notice' and references an Appendix 3Y form, which is a standard Australian Securities Exchange (ASX) form used to notify changes in directors' interests in securities. The content details the change in entitlement of a director to options and conditional rights, including dates and quantities. There is no financial performance data, earnings information, or management discussion. The document is a regulatory announcement about insider share transactions by a company director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length and detail support this classification with high confidence.
2013-04-08 English
Appendix 3Y Notice - Change Direcror's Interest 1
Director's Dealing Classification · 100% confidence The document is titled 'Change of Director’s Interest Notice' and references an Appendix 3Y Notice related to a change in entitlement of a director to non-quoted options. It is a notification about a director's personal share transactions or changes in their share entitlements. The document is short (1421 characters) and does not contain financial statements or company performance data. This fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives. Therefore, the correct classification is DIRS.
2013-04-07 English
Appendix 3B - Reconciliation of Issued Securities 13 pages 565.6KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B notice from Phosphagenics Limited, dated 5 April 2013, detailing the exercise and reconciliation of non-quoted securities, the issue of new shares upon exercise of options, and changes in conditional rights. Appendix 3B is a standard form used in Australian Securities Exchange (ASX) announcements to notify the market of new issues of securities, applications for quotation of additional securities, and related agreements. The document includes detailed information about the number and class of securities issued, exercise prices, expiry dates, and compliance with ASX listing rules. It is not a financial report, earnings release, or management discussion but a regulatory announcement about capital changes. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length (15,000 characters) and content confirm it is the actual announcement, not just a brief notice or report publication announcement.
2013-04-07 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.